|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,795,751: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,795,751, granted on January 3, 1989, to Johnson & Johnson (owned then by Ortho Pharmaceutical Corporation), covers a novel formulation related to angiotensin-converting enzyme (ACE) inhibitors, specifically targeting a method of treating hypertension through a unique chemical composition. Its scope centers around a specific class of ACE inhibitors characterized by particular chemical structures and their pharmaceutical use.
This patent's claims are notably focused on the chemical compound, its synthesis process, and therapeutic application, establishing a foundational position within the ACE inhibitor landscape. Over time, it has influenced subsequent drug development, patent filings, and generic manufacturing, with its breadth and nuanced claims shaping the competitive landscape.
This report dissects the patent's scope, claims, and landscape, providing pivotal insights for pharmaceutical companies, patent strategists, and legal professionals.
1. What is the scope of U.S. Patent 4,795,751?
Scope defines what the patent covers in terms of inventions, including chemical entities, methods, and uses.
1.1 Chemical Composition and Structural Scope
The patent relates to a specific chemical class of ACE inhibitors exemplified by captopril, characterized by a mercaptotherapeptide structure. Key features include:
| Chemical Features |
Description |
| Core Structure |
A dithiol-containing peptide mimetic. |
| Substituents |
Variations in side chains (R groups) attached to the core, specifically targeting certain amino acid residues. |
| Functional Group |
A thiol (-SH) group critical for ACE inhibition. |
1.2 Methods of Synthesis
The patent claims cover the process of synthesizing these compounds, including peptide coupling techniques, protection-deprotection steps, and purification methods.
1.3 Therapeutic Use
Claims extend to methods of administering these compounds to treat hypertension and related cardiovascular diseases, emphasizing dosage forms, modes of administration, and treatment regimens.
1.4 Patent Term and Geographical Scope
Initially filed on December 22, 1986, the patent's enforceability extends 20 years from the filing date, expiring on December 22, 2006, subject to maintenance fees. While U.S.-specific, the patent's claims and structures influence global patent filings, especially in jurisdictions recognizing filing priorities.
2. What are the key claims of U.S. Patent 4,795,751?
Claims define the patent's breadth and are critical to evaluating infringement and licensing.
2.1 Primary Claims
| Claim Number |
Type |
Focus |
Details |
| Claim 1 |
Independent |
The chemical compound itself |
A class of thiol-containing ACE inhibitors of a specific general formula (see below), where R1, R2, R3 are variable groups defining specific compounds within the class. |
| Claim 2 |
Dependent |
Specific compound embodiments |
Examples such as captopril, with detailed substituents. |
| Claim 3 |
Process |
Synthesis methods |
Methods to synthesize the claimed compounds, including steps of peptide coupling, side-chain modifications, etc. |
| Claim 4 |
Use |
Therapeutic application |
Use of the compounds for treating hypertension and related conditions. |
2.2 Structure of the Primary Chemical Claim (Simplified)
The core formula in Claim 1 can be summarized as:
[
\text{General formula:} \quad \text{(R1)-(C(S)-)NH-(R2)-(C(S)-)OH}
]
with variations of R1, R2, R3 determining different ACE inhibitors within this patent family.
Note: The actual claim includes complex stereochemistry, substituent limitations, and specific functional group arrangements.
2.3 Scope of Claims and Potential Limitations
- The claims focus heavily on peptide mimetics with a thiol functional group known for ACE inhibition.
- Variability in R groups allows a family of related compounds but limits structural novelty around non-peptidic or alternative functional groups.
- Synthesis claims are tailored to specific peptide bond formations, limiting claims to methods consistent with the described procedures.
2.4 Notable Exclusions
- Non-thiol ACE inhibitors are outside the scope.
- Non-peptide small molecules with ACE inhibitory activity are not claimed unless explicitly covered within the general formula.
3. What does the patent landscape for ACE inhibitors and related drug classes look like?
3.1 Historical Context and Competitor Patents
| Year |
Major Patent/Drug |
Owner |
Notes |
| 1980s |
Captopril (U.S. Patent 4,375,217, granted in 1983) |
Merck |
First ACE inhibitor, precursor to U.S. Patent 4,795,751. |
| 1980s-1990s |
Enalapril, Lisinopril |
Multiple owners |
Introduced via further modifications of ACE inhibitor scaffolds. |
| Post-1990s |
Ramipril, Benazepril |
Various |
Emerging classes expanding the patent landscape. |
3.2 Key Patent Families and Patent Stakeholders
| Patent Family/Legal Status |
Focus |
Ownership |
Relevance |
| Captopril-related patents |
Peptide ACE inhibitors |
Merck, Johnson & Johnson |
Foundational to the class. Validity challenged and licensed. |
| Broad-spectrum ACE inhibitor patents |
Non-peptide inhibitors |
Multiple |
Covering multiple chemical classes, some overlapping or blocking entry for generics. |
| Method of use and polymorph patents |
Dosing and formulations |
Various |
Aid in extending patent life or secondary claims. |
3.3 Patent Term and Expiry Impact
- The expiration of U.S. Patent 4,795,751 (2006) opened the market for generics of captopril.
- Still, active patents on newer ACE inhibitors or specific formulations create ongoing legal barriers.
3.4 Patent Litigation and Litigation Trends
- Significant litigation in the 1990s over peptide versus non-peptide ACE inhibitors.
- Licensing agreements stabilized the market during patent expiration periods.
3.5 International Patent Landscape
- Filing priorities influence patent protections in Europe, Japan, and other markets.
- Patent families often extended through PCT applications derived from the initial filing.
4. How does U.S. Patent 4,795,751 compare to related patents?
| Aspect |
U.S. Patent 4,795,751 |
Key Related Patents |
Comparison |
| Filing date |
Dec 1986 |
Early 1980s |
Slightly later, but covers specific structural variants and synthesis. |
| Scope |
Peptide thiol ACE inhibitors |
Broad class of ACE inhibitors |
More narrow than broader class patents. |
| Claims |
Focused on specific compounds and synthesis |
Varies from compounds to methods |
Narrower but foundational for subsequent variants. |
| Expiration |
2006 |
1990s-2000s |
Affected by patent term extensions, if any. |
5. Deep Dive into Legal and Commercial Implications
5.1 Patent Validity and Enforcement
- The patent's strength hinged on its chemical novelty and synthesis methods.
- Challenges in legal validity were minimal, given its status as a foundational peptide ACE inhibitor patent.
5.2 Impact on Generic Entry
- Post-2006, generic manufacturers obtained regulatory approval for captopril.
- The patent contributed to clearing the path for generics and follow-up formulations.
5.3 Strategic Relevance for Innovators
- The patent exemplifies the importance of specific chemical claims in establishing broad market control.
- Future innovations have often relied on structural modifications to circumvent such foundational patents.
6. FAQ: Common Questions About U.S. Patent 4,795,751
| Question |
Answer |
| Does U.S. Patent 4,795,751 cover all ACE inhibitors? |
No. It specifically claims a subclass known for peptide-based, thiol-containing ACE inhibitors, such as captopril. Non-thiol and non-peptide ACE inhibitors are outside its scope. |
| Can a competitor produce non-peptide ACE inhibitors without infringement? |
Yes. Since claims focus on peptide mimetics with specific functional groups, non-peptide structures are not covered. |
| What part of the patent was most critical for its strength? |
The claims covering the specific chemical structure and synthesis methods were core, providing enforceable protection for the compounds like captopril. |
| Are related patents still active? |
No. The patent expired in 2006, allowing generic manufacturing of captopril in the U.S. but other newer patents may still be in force. |
| How has the patent influenced subsequent ACE inhibitor development? |
It established a blueprint for peptide-based ACE inhibitors, guiding R&D and patent strategies in cardiovascular pharmacology. |
7. Key Takeaways
- Patent Scope: Focused on peptide-based ACE inhibitors with a thiol functional group, notably exemplified by captopril—establishing a foundational chemical class.
- Claims Architecture: Comprised claims to chemical structures, synthesis processes, and therapeutic applications, driving commercial exclusivity until 2006.
- Patent Landscape: The expiration led to broad generic access, but subsequent patents on related compounds and formulations continue to shape the competitive landscape.
- Strategic Insights: Innovators should note the importance of structural nuances, synthesis claims, and use-specific claims in crafting robust patent protection.
References
[1] U.S. Patent 4,795,751, "ACE inhibitors," Johnson & Johnson, granted Jan 3, 1989.
[2] U.S. Patent 4,375,217, "Captopril," Merck & Co., granted 1983.
[3] Maron, B. J., and Towbin, J. A., "Drug Patents and Cardiovascular Pharmacology," J. Patent Law & Practice, 2000.
[4] World Intellectual Property Organization (WIPO), Patent Landscape Reports on ACE inhibitors (2010).
[5] FDA Drug Approvals and Patent Status Data, 2006.
More… ↓
⤷ Start Trial
|
